ARTICLE | Finance
Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS
By BioCentury Staff
December 16, 2023 1:47 AM UTC
Building on the antibody-drug conjugate programs gained through the acquisition of Seagen Inc., Pfizer Inc. (NYSE:PFE) signed a licensing deal with Nona Bioscience to access HBM9033, an ADC targeting MSLN. Pfizer will pay $53 million in upfront and near-term payments, with the HBM Holdings Ltd. (HKEX:02142) subsidiary eligible for up to $1.05 billion in milestones and undisclosed royalties. Pfizer is the latest company to do an ADC deal with a company with Asian ties, and the licensing deal gives the pharma a candidate against a target absent from Seagen’s large pipeline.
FDA approved Padcev enfortumab vedotin-ejfv from Seagen and Astellas Pharma Inc. (Tokyo:4503) plus Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) to treat locally advanced or metastatic urothelial carcinoma. FDA previously granted accelerated approval to this combination for patients who are ineligible for cisplatin-containing chemotherapy. In October, the combination set a new standard for urothelial cancer after data from the Phase III EV-302/KEYNOTE-A39 trial presented at the ESMO Congress 2023 showed it nearly doubled survival…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650939/dec-15-quick-takes-pfizer-nona-in-adc-deal